NEO · NeoGenomics, Inc.
$16.59
+1.22% last session
End-of-day data · close of 2026-10-23
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
48.4
Dividend yield
0.0%
Beta
1.78
Avg volume
2M
Employees
2K
Daily Change %
1.22%
5 Days Change
1.04%
10 Days Change
-1.72%
30 Days Change
-15.18%
60 Days Change
-1.19%
Month to Day Change
-6.69%
Year to Day Change
41.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NEO
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-06
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | StoneX | Maintains | Buy | $16.00 → $20.00 |
| 2026-10-06 | Needham | Maintains | Buy | $19.00 → $22.00 |
| 2026-10-06 | BTIG | Upgrade | Neutral → Buy | $0.00 → $28.00 |
| 2026-07-29 | Needham | Maintains | Buy | $15.00 → $19.00 |
| 2026-07-24 | Benchmark | Maintains | Buy | $11.00 → $16.00 |
| 2026-04-29 | Benchmark | Upgrade | Hold → Buy | $0.00 → $11.00 |
| 2026-04-29 | TD Cowen | Maintains | Buy | $13.00 → $14.00 |
| 2026-04-29 | Leerink Partners | Upgrade | Market Perform → Outperform | $12.00 → $25.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 5.5% below the 50-day MA ($17.56).
- bullish: Price vs 200-day MA: Trading 30.9% above the 200-day MA ($12.67).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($7.19) and high ($19.91).
NEO Price Chart
Loading chart for NEO…
Fundamentals
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.